keyword
MENU ▼
Read by QxMD icon Read
search

Antipsychotic augmentation

keyword
https://www.readbyqxmd.com/read/28634087/treatment-with-levetiracetam-improves-cognition-in-a-ketamine-rat-model-of-schizophrenia
#1
Ming Teng Koh, Yi Shao, Sharon Rosenzweig-Lipson, Michela Gallagher
Imbalance in neural excitation and inhibition is associated with behavioral dysfunction in individuals with schizophrenia and at risk for this illness. We examined whether targeting increased neural activity with the antiepileptic agent, levetiracetam, would benefit memory performance in a preclinical model of schizophrenia that has been shown to exhibit hyperactivity in the hippocampus. Adult rats exposed to ketamine subchronically during late adolescence showed impaired hippocampal-dependent memory performance...
June 17, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28629889/comparison-of-the-effectiveness-of-brand-name-and-generic-antipsychotic-drugs-for-treating-patients-with-schizophrenia-in-taiwan
#2
Chih-Wei Hsu, Sheng-Yu Lee, Liang-Jen Wang
The purpose of this nationwide population-based study is to compare the long-term effectiveness of brand-name antipsychotics with generic antipsychotics for treating schizophrenia. We identified patients with schizophrenia who were prescribed antipsychotics from a random sample of one million records from Taiwan's National Health Insurance database, observed between January 1, 2000 and December 31, 2012. Only those with no prior use of antipsychotics for at least 180days were included. We selected patients who were prescribed brand-name risperidone (N=404), generic risperidone (N=145), brand-name sulpiride (N=334), or generic sulpiride (N=991)...
June 16, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28626273/combined-antipsychotics-and-electroconvulsive-therapy-in-an-acutely-psychotic-patient-with-treatment-resistant-schizophrenia
#3
Ruth Rayikanti, Iga Lentowicz, Badari Birur, Li Li
Treatment of patients with Treatment-resistant Schizophrenia (TRS), who fail to respond to multiple antipsychotic trials, including clozapine (CLZ), is challenging. Several alternative strategies are reported in studies, one of which includes augmenting antipsychotics (AP) with Electroconvulsive therapy (ECT). We discuss a case of an acutely psychotic patient with TRS who responded effectively and sustained remission to this strategy which was ECT combined with two AP, CLZ and aripiprazole. Notable improvement in clinical and cognitive outcomes was seen with just five right unilateral ECT sessions, CLZ titrated up to 62...
May 15, 2017: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/28617392/-panic-disorder-clinical-phenomena-and-treatment-options
#4
Yu P Sivolap
Panic disorder is a common mental disease with high psychiatric comorbidity. It is considered that a combination of genetic predisposition and a special psychic vulnerability plays a key role in the occurrence of panic disorder. Clinically proven efficacy in the treatment of panic disorder have benzodiazepines, tricyclic antidepressants, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors and selective serotonin and norepinephrine reuptake inhibitors; antidepressants from other pharmaceutical groups are also used...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/28579786/topiramate-add-on-treatment-associated-with-normalization-of-prolactin-levels-in-a-patient-with-schizophrenia
#5
Yinglin Huang, Huan Ma, Yuan Wang, Miao Peng, Gang Zhu
Topiramate has been used increasingly in the management of psychiatric conditions. Clinical trials demonstrated that topiramate augmentation was effective in controlling negative symptoms in schizophrenia. This case report presents a case of a 38-year-old man with schizophrenia who achieved full negative symptom remission upon the adjunctive use of topiramate. However, the remarkable finding of this case is the concomitant decrease in the level of prolactin when topiramate (50 mg/day) was started and the rebound after discontinuation of topiramate...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28579072/the-impact-of-comorbid-post-traumatic-stress-disorder-in-patients-with-major-depressive-disorder-on-clinical-features-pharmacological-treatment-strategies-and-treatment-outcomes-results-from-a-cross-sectional-european-multicenter-study
#6
Markus Dold, Lucie Bartova, Alexander Kautzky, Daniel Souery, Julien Mendlewicz, Alessandro Serretti, Stefano Porcelli, Joseph Zohar, Stuart Montgomery, Siegfried Kasper
This international, multicenter, cross-sectional study comprising 1346 adult in- and outpatients with major depressive disorder (MDD) investigated the association between MDD as primary diagnosis and comorbid post-traumatic stress disorder (PTSD). In a cross-sectional data collection process, the presence of comorbid PTSD was determined by the Mini International Neuropsychiatric Interview (MINI) and the patients' socio-demographic, clinical, psychopharmacological, and response information were obtained. Clinical features between MDD with and without concurrent PTSD were compared using descriptive statistics, analyses of covariance (ANCOVA), and binary logistic regression analyses...
May 31, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28541645/raloxifene-plus-antipsychotics-versus-placebo-plus-antipsychotics-in-severely-ill-decompensated-postmenopausal-women-with-schizophrenia-or-schizoaffective-disorder-a-randomized-controlled-trial
#7
Mark Weiser, Linda Levi, Shimon Burshtein, Michal Hagin, Valentin P Matei, Delia Podea, Ioana Micluția, Alexandru Tiugan, Bogdan Păcală, Iosif Gabos Grecu, Adam Noy, Daisy Zamora, John M Davis
OBJECTIVE: Several single-center studies have found raloxifene, an estrogen agonist, to be effective in ameliorating symptoms of schizophrenia in stable patients as augmentation of antipsychotics. This multicenter study assessed whether raloxifene plus antipsychotic treatment, in comparison to placebo plus antipsychotics, improves symptoms or cognition in severely ill decompensated schizophrenia patients. METHODS: In this 16-week, double-blind, randomized, placebo-controlled study, 200 severely ill, decompensated postmenopausal women who met DSM-IV-TR criteria for schizophrenia or schizoaffective disorder were recruited from January 2011 to December 2012 and were randomized to receive either raloxifene 120 mg/d plus antipsychotics or placebo plus antipsychotics...
May 23, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28539959/tardive-dystonia-related-with-aripiprazole
#8
Sunghwan Kim, Seung-Yup Lee, MinSeob Kim, Kyoung-Uk Lee
Tardive dystonia is characterized by sustained, generally slow involuntary twisting movements. It is estimated to occur at a frequency of 1% to 4% among patients who are taking an antipsychotic agent. Unlike the first generation antipsychotics, the second generation antipsychotics are less likely to cause neuroleptic-induced movement disorder. For aripiprazole, only a few cases have been reported for tardive dystonia. We present a young male, who developed a severe tardive dystonia after taking aripiprazole for 5 years...
May 2017: Psychiatry Investigation
https://www.readbyqxmd.com/read/28514486/efficacy-of-42-pharmacologic-cotreatment-strategies-added-to-antipsychotic-monotherapy-in-schizophrenia-systematic-overview-and-quality-appraisal-of-the-meta-analytic-evidence
#9
Christoph U Correll, Jose M Rubio, Gabriella Inczedy-Farkas, Michael L Birnbaum, John M Kane, Stefan Leucht
Importance: Limited treatment responses in schizophrenia prompted the testing of combining an antipsychotic drug treatment with a second psychotropic medication. A comprehensive evaluation of the efficacy of multiple medication combinations is missing. Objective: To summarize and compare the meta-analytically determined efficacy of pharmacologic combination strategies of antipsychotic drugs in adults with schizophrenia. Data Sources: Systematic search of PubMed and PsycInfo until May 13, 2016...
May 17, 2017: JAMA Psychiatry
https://www.readbyqxmd.com/read/28484390/spatiotemporal-mapping-techniques-show-clozapine-impairs-neurogenic-and-myogenic-patterns-of-activity-in-the-colon-of-the-rabbit-in-a-dose-dependent-manner
#10
Susanna Every-Palmer, Roger G Lentle, Gordon Reynolds, Corrin Hulls, Paul Chambers, Helen Dunn, Pete M Ellis
Background: Clozapine, an antipsychotic used in treatment-resistant schizophrenia, has adverse gastrointestinal effects with significant associated morbidity and mortality. However, its effects on defined patterns of colonic contractile activity have not been assessed. Method: We used novel radial and longitudinal spatiotemporal mapping techniques, combined with and monitoring of ambient lumen pressure, in ex vivo preparations of triply and of singly haustrated portions of rabbit colon. We identified the contractile patterns of mass peristalses, fast phasic, and ripple contractions and directly qualified the effects of clozapine, at concentrations of 10 μmol/L, 20 μmol/L, and 30 μmol/L, and of norclozapine, the main metabolite of clozapine, on contractile patterns...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28474552/new-directions-in-the-use-of-brain-stimulation-interventions-in-patients-with-obsessive-compulsive-disorder
#11
Bernardo Dell'Osso, Laura Cremaschi, Lucio Oldani, Alfredo Carlo Altamura
Obsessive-Compulsive Disorder (OCD) is a highly disabling condition with early onset and chronic course in most of the affected patients. In addition, OCD may show high comorbidity and suicide attempt rates, which worsen the overall burden of the disease for patients and their caregivers. First-line treatments for OCD consist of pro-serotonergic compounds and cognitive-behavioral therapy. Nonetheless, many patients show only limited benefit from such interventions and require additional "next-step" interventions, including augmentative antipsychotics and glutamate-modulating agents...
May 4, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28455126/neurochemical-arguments-for-the-use-of-dopamine-d4-receptor-stimulation-to-improve-cognitive-impairment-associated-with-schizophrenia
#12
Mei Huang, Sunoh Kwon, Wenqi He, Herbert Y Meltzer
BACKGROUND: Dopamine (DA) D4 receptors have been implicated in schizophrenia and the ability of some atypical antipsychotic drugs (APDs) to improve the cognitive impairment associated with schizophrenia (CIAS). Systemic administration of a D4 agonist, PD168077, at a sub-effective dose, together with a sub-effective dose of lurasidone, an atypical APD which is a weak D4 receptor antagonist, reversed the deficit in novel object recognition (NOR) in rats treated subchronically with phencyclidine (PCP), a rodent model of CIAS...
April 25, 2017: Pharmacology, Biochemistry, and Behavior
https://www.readbyqxmd.com/read/28410959/the-involvement-of-bdnf-creb-signaling-pathways-in-the-pharmacological-mechanism-of-combined-ssri-antipsychotic-treatment-in-schizophrenia
#13
Reef Einoch, Orly Weinreb, Nina Mandiuk, Moussa B H Youdim, Warren Bilker, Henry Silver
Previous studies into the mechanism of SSRI-antipsychotic synergism in our laboratory identified unique changes in the brain, particularly in the γ-aminobutyric acid (GABA)-A receptor and its modulators. This study examined the role of brain derived neurotrophic factor (BDNF)-cAMP response element binding (CREB) protein signaling pathways, including protein kinase B (AKT), glycogen synthase kinase (GSK)-3β and related molecules in the molecular response to haloperidol, fluvoxamine, combined haloperidol+fluvoxamine and clozapine treatments in rat frontal cortex, hippocampus and primary cortical neuronal cultures...
April 11, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28403623/lithium-a-classic-drug-frequently-discussed-but-sadly-seldom-prescribed
#14
Olga Zivanovic
OBJECTIVE: Distinguished authors in the field have repeatedly alerted psychiatrists of the alarming trends in the treatment of bipolar disorders: decline of lithium use, paralleled by the increase of prescribing anticonvulsants and second-generation antipsychotic drugs. Research has been conducted in order to explore the factors that led to this development and to provide arguments for the need to reverse this trend. METHOD: This paper represents a narrative review of the literature containing retrieved research articles focusing on the efficacy of lithium...
April 1, 2017: Australian and New Zealand Journal of Psychiatry
https://www.readbyqxmd.com/read/28349992/central-neuromodulators-for-treating-functional-gi-disorders-a-primer
#15
REVIEW
W Harley Sobin, Thomas W Heinrich, Douglas A Drossman
Patients with functional GI disorders (FGIDs) are commonplace in the gastroenterologist's practice. A number of these patients may be refractory to peripherally acting agents, yet respond to central neuromodulators. There are benefits and potential adverse effects to using TCAs, SSRIs, SNRIs, atypical antipsychotics, and miscellaneous central neuromodulators in these patients. These agents can benefit mood, pain, diarrhea, constipation, nausea, sleep, and depression. The mechanisms by which they work, the differences between classes and individual agents, and the various adverse effects are outlined...
May 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28347261/dopamine-d4-receptor-stimulation-contributes-to-novel-object-recognition-relevance-to-cognitive-impairment-in-schizophrenia
#16
Masanori Miyauchi, Nichole M Neugebauer, Herbert Y Meltzer
Several atypical antipsychotic drugs (APDs) have high affinity for the dopamine (DA) D4 receptor, but the relevance to the efficacy for the treatment of cognitive impairment associated with schizophrenia (CIAS) is poorly understood. The aim of this study was to investigate the effects of D4 receptor stimulation or blockade on novel object recognition (NOR) in normal rats and on the sub-chronic phencyclidine (PCP)-induced novel object recognition deficit. The effect of the D4 agonist, PD168077, and the D4 antagonist, L-745,870, were studied alone, and in combination with clozapine and lurasidone...
April 2017: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/28344764/atypical-antipsychotics-recent-research-findings-and-applications-to-clinical-practice-proceedings-of-a-symposium-presented-at-the-29th-annual-european-college-of-neuropsychopharmacology-congress-19-september-2016-vienna-austria
#17
REVIEW
Robin Murray, Christoph U Correll, Gavin P Reynolds, David Taylor
Available evidence suggests that second-generation atypical antipsychotics are broadly similar to first-generation agents in terms of their efficacy, but may have a more favourable tolerability profile, primarily by being less likely to cause extrapyramidal symptoms. However, atypical antipsychotics are variably associated with disturbances in the cardiometabolic arena, including increased body weight and the development of metabolic syndrome, which may reflect differences in their receptor binding profiles...
March 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28338544/associations-between-medication-class-and-subsequent-augmentation-of-depression-treatment-in-privately-insured-us-adults
#18
Omid Ameli, Rene Soria-Saucedo, Eric G Smith, Howard J Cabral, Marina Soley-Bori, Lewis E Kazis
IMPORTANCE: Treatment augmentation is an important clinical decision in the pharmacotherapy for depression, yet few studies have examined the rates of treatment augmentation by medication class. OBJECTIVE: The aim of this study was to examine which initial pharmacotherapies for depression are more likely than others to result in subsequent treatment augmentation. METHODS: This study is a retrospective cohort analysis of administrative data of 214,705 privately insured US adults between the age of 18 and 64 years who were diagnosed with a new episode of depression in 2009...
June 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28331329/successful-treatment-for-psychomotor-agitation-in-neuromyelitis-optica-spectrum-disorder-with-trazodone-risperidone-combination-a-case-report
#19
Zui Narita, Harumasa Takano, Tomiki Sumiyoshi
Neuromyelitis optica (NMO) is a relapsing disease that typically affects the spinal cord and optic nerves. So far, a few studies have reported pharmacologic treatment for psychiatric symptoms in patients with NMO spectrum disorder (NMOSD). However, no literature has described psychomotor agitation associated with the disease and its treatment. We report an 84-year-old woman with NMOSD whose psychomotor agitation was effectively treated with a combination of trazodone and risperidone. Our observation suggests the ability of augmentation of antipsychotic drugs with antidepressants to ameliorate psychotic symptoms associated with NMOSD...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28318897/efficacy-of-off-label-augmentation-in-unipolar-depression-a-systematic-review-of-the-evidence
#20
REVIEW
Julia Kleeblatt, Felix Betzler, Laura L Kilarski, Tom Bschor, Stephan Köhler
Treatment of unipolar depression with currently available antidepressants is still unsatisfactory. Augmentation with lithium or second generation antipsychotics is an established practice in non-responders to antidepressant monotherapy, but is also associated with a substantial non-response rate and with non-tolerance. Based on a systematic review of the literature, including meta-analyses, randomized controlled trials (RCTs), non-randomized comparative studies and case studies, off-label augmentation agents (administered in addition to an antidepressant, without FDA approval for treatment of MDD) were identified and evaluated regarding their efficacy using levels of evidence...
March 16, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
keyword
keyword
86291
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"